Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-181 + SC-004 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-181 | ABBV181|ABBV 181|Budigalimab | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67 | ABBV-181 (budigalimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32770720). | |
SC-004 | SC004|SC 004 | SC-004 is a monoclonal anti-tumor-associated antigen (TAA) antibody in conjugation with an undisclosed cytotoxic agent, which may target TAA-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03138408 | Phase I | SC-004 ABBV-181 + SC-004 | SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers | Terminated | USA | 0 |